{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:27:23Z","timestamp":1794526043030,"version":"4.9.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Achievement Transformation Demonstration Project of the Key research and development (R&D) Program of Science & Technology Department of Chengdu","award":["2023-YF09-00003-SN"],"award-info":[{"award-number":["2023-YF09-00003-SN"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,24]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Plaque psoriasis, primary sclerosing cholangitis, and ulcerative colitis are all immune-mediated inflammatory diseases. Their coexistence is extremely rare, and therapeutic management remains challenging due to shared immunopathogenic mechanisms and limited treatment experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 36-year-old woman presented with pruritic red papules and plaques covering scales all over the body for more than 10 years. She also reported liver dysfunction for over 3 years and chronic diarrhea exceeding 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Based on her medical history, clinical manifestations, histopathological findings, and examinations, she was diagnosed with plaque psoriasis, primary sclerosing cholangitis, and ulcerative colitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient had shown an inadequate response to oral steroids and adalimumab. Upon presentation to our clinic, she was assessed as having moderate plaque psoriasis (Psoriasis Area and Severity Index: 6.0, body surface area: 10.0%) and was treated with oral apremilast (titrated up to 60\u2009mg\/d), ursodeoxycholic acid (1000\u2009mg\/d), and phosphatidylcholine (1368\u2009mg\/d).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>After 48 weeks of treatment, the patient achieved complete clearance of psoriatic lesions, marked reduction of pruritus, stable liver function, decreased diarrhea frequency, and no adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case underscores the potential response and tolerability of apremilast as an alternative treatment for psoriasis coexisting with autoimmune liver disease and inflammatory bowel disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045232","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:02:24Z","timestamp":1761332544000},"page":"e45232","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Apremilast as a novel therapeutic option for psoriasis coexisting primary sclerosing cholangitis and ulcerative colitis: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7027-3560","authenticated-orcid":false,"given":"Jingya","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Dermatology & Venerology, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Dermatology & Venerology, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Dermatology & Venerology, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Dermatology & Venerology, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyao","family":"Mi","sequence":"additional","affiliation":[{"name":"Department of Dermatology & Venerology, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology & Venerology, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology & Venerology, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261112","first-page":"1301","article-title":"Psoriasis.","volume":"397","author":"Griffiths","year":"2021","journal-title":"JNWN"},{"key":"R2-20261112","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/ecco-jcc\/jjz152","article-title":"Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease-a systematic review and meta-analysis.","volume":"14","author":"Alinaghi","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R3-20261112","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.cgh.2023.04.004","article-title":"Recent advances in the management of primary sclerosing cholangitis.","volume":"21","author":"Assis","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-20261112","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","article-title":"Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis.","volume":"161","author":"Barberio","year":"2021","journal-title":"Gastroenterology"},{"key":"R5-20261112","doi-asserted-by":"crossref","first-page":"2281658","DOI":"10.1080\/07853890.2023.2281658","article-title":"Integrated analysis of Mendelian randomization and Bayesian colocalization reveals bidirectional causal association between inflammatory bowel disease and psoriasis.","volume":"55","author":"Cai","year":"2023","journal-title":"Ann Med"},{"key":"R6-20261112","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis.","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R7-20261112","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/1346-8138.17270","article-title":"Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: results of a post-marketing surveillance study.","volume":"51","author":"Ohtsuki","year":"2024","journal-title":"J Dermatol"},{"key":"R8-20261112","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/bph.14667","article-title":"Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.","volume":"176","author":"Li","year":"2019","journal-title":"Br J Pharmacol"},{"key":"R9-20261112","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nat Genet"},{"key":"R10-20261112","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/09546634.2020.1836313","article-title":"Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review.","volume":"33","author":"Conforti","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R11-20261112","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/liv.12028","article-title":"Non-IBD immunological diseases are a risk factor for reduced survival in PSC.","volume":"33","author":"Rupp","year":"2013","journal-title":"Liver Int"},{"key":"R12-20261112","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: classical vs. paradoxical. The Yin-Yang of TNF and type I interferon.","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front Immunol"},{"key":"R13-20261112","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1684\/ejd.2023.4427","article-title":"Psoriasis vulgaris associated with primary biliary cholangitis: IL-23 links skin manifestations and liver function.","volume":"33","author":"Kamura","year":"2023","journal-title":"Eur J Dermatol"},{"key":"R14-20261112","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.cgh.2023.01.014","article-title":"Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study.","volume":"21","author":"Schregel","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R15-20261112","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R16-20261112","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.4155\/fmc-2023-0101","article-title":"PDE4 inhibitors for disease therapy: advances and future perspective.","volume":"15","author":"Du","year":"2023","journal-title":"Future Med Chem"},{"key":"R17-20261112","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/ijms18061276","article-title":"PDE4 inhibition and inflammatory bowel disease: a novel therapeutic avenue.","volume":"18","author":"Spadaccini","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R18-20261112","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/biomedicines11082249","article-title":"Inflammatory bowel disease: emerging therapies and future treatment strategies.","volume":"11","author":"Bretto","year":"2023","journal-title":"Biomedicines"},{"key":"R19-20261112","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities.","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"R20-20261112","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaut.2016.05.005","article-title":"CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease.","volume":"72","author":"Liberal","year":"2016","journal-title":"J Autoimmun"},{"key":"R21-20261112","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1124\/jpet.113.204933","article-title":"Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4.","volume":"347","author":"Gobejishvili","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"R22-20261112","doi-asserted-by":"crossref","first-page":"e2022179","DOI":"10.5826\/dpc.1204a179","article-title":"Apremilast in psoriasis patients with serious comorbidities: a case series and systematic review of literature.","volume":"12","author":"Tsentemeidou","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"R23-20261112","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:02:04Z","timestamp":1794524524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":23,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045232","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"2025-05-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}